Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9264)
All Articles published online
|
Publishing Process of This Article
|
Oct 28, 2014 (publication date) through Nov 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Wang B, Lv ZF, Wang YH, Wang H, Liu XQ, Xie Y, Zhou XJ. Standard triple therapy for |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i40/14973.htm |
| Number | Citing Articles |
| 1 |
Yi Hu, Yin Zhu, Nong-Hua Lu. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Frontiers in Cellular and Infection Microbiology 2017; 7 doi: 10.3389/fcimb.2017.00168
|
| 2 |
Ben-Gang Zhou, Yu-Zhou Mei, Min Zhang, Xin Jiang, Yao-Yao Li, Yan-Bing Ding. High-dose dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis with trial sequential analysis. Therapeutic Advances in Gastroenterology 2023; 16 doi: 10.1177/17562848221147756
|
| 3 |
Ying Zhou, Ziqing Ye, Yuhuan Wang, Ye Zhang, Zifei Tang, Weili Yan, Yuan Jiang, Ying Huang. Comparison of four different regimens against Helicobacter pylori as a first‐line treatment: A prospective, cross‐sectional, comparative, open trial in Chinese children. Helicobacter 2020; 25(2) doi: 10.1111/hel.12679
|
| 4 |
Ben‐Gang Zhou, Ling‐Xiao Chen, Bo Li, Lin‐Yan Wan, Yao‐Wei Ai. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis with trial sequential analysis. Helicobacter 2019; 24(5) doi: 10.1111/hel.12651
|
| 5 |
Cheng Shen, Changping Li, Muhan Lv, Xiaosong Dai, Caiping Gao, Liangping Li, Qin Zhang, Wen Pan, Chao Liu, Sijing Han, Yang Zhang, Shunbin Ding, Hong Deng, Yong Yao, Jianyu Xu, Mingyong Wei, Haiyan Shi, Peijie Yuan, Xiaoyan Yang, Yi Jian, Jing Shan, Yan Liu, Zonghua Chen, Xuejie Deng, Fei Liu, Lijuan Deng, Xianfei Zhong, Hong Li, Shaoya He, Li Chen, Gang Liu, Hairong Xu, Yuquan Zhong, Hua Shi, Jiangang Ren.
The prospective multiple-centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy for
H. pylori
infection in Sichuan areas
. Annals of Medicine 2022; 54(1): 426 doi: 10.1080/07853890.2022.2031269
|
| 6 |
Lili Yang, Ao Zou, Huihua Wu, Hai Guo, Fangting Zhang, Bing Zou, Junping Wang, Emily Chia-Yu Su. Application of Visual Gene Clip-Based Tailored Therapy for the Eradication of Helicobacter pylori. BioMed Research International 2021; 2021: 1 doi: 10.1155/2021/6150628
|
| 7 |
Chang-Gen Ye, Xiao-Jia Zhu, Na Hu, Bai-Hui Wu, Jun Fang, Li Yang. Efficacy and safety of high-dose dual therapy in eradicating Helicobacter pylori. World Chinese Journal of Digestology 2024; 32(9): 665 doi: 10.11569/wcjd.v32.i9.665
|
| 8 |
Jie Hu, Hao Mei, Na‐yun Su, Wen‐jing Sun, De‐kui Zhang, Li‐lin Fan, Ping He, Jie Pan, Xing‐wei Wang, Pei‐ying Zou, Yu‐xiang Liu, Yan Guo, Chun‐Hui Lan. Eradication rates of Helicobacter pylori in treatment‐naive patients following 14‐day vonoprazan‐amoxicillin dual therapy: A multicenter randomized controlled trial in China. Helicobacter 2023; 28(4) doi: 10.1111/hel.12970
|
| 9 |
Anthony O'Connor, Javier P. Gisbert, Colm O'Morain, Spiros Ladas. Treatment of Helicobacter pylori Infection 2015. Helicobacter 2015; 20(S1): 54 doi: 10.1111/hel.12258
|
| 10 |
Romelia Pop, Alexandru-Flaviu Tăbăran, Andrei Paul Ungur, Andrada Negoescu, Cornel Cătoi. Helicobacter Pylori-Induced Gastric Infections: From Pathogenesis to Novel Therapeutic Approaches Using Silver Nanoparticles. Pharmaceutics 2022; 14(7): 1463 doi: 10.3390/pharmaceutics14071463
|
| 11 |
Hui Ye, Zong-ming Shi, Yao Chen, Jing Yu, Xue-zhi Zhang. Innovative Perspectives of Integrated Chinese Medicine on H. pylori. Chinese Journal of Integrative Medicine 2018; 24(11): 873 doi: 10.1007/s11655-017-2934-6
|
| 12 |
Jing Yu, Hui Ye, Jiang Li, Ning Li, Zong-ming Shi, Xue-zhi Zhang, Youn C. Kim. The Antibacterial Activity of Mass Galla Chinesis et Camelliae Fermentata on Helicobacter pylori Infection. Evidence-Based Complementary and Alternative Medicine 2018; 2018(1) doi: 10.1155/2018/1491732
|
| 13 |
Qiuyue Huang, Xiaofen Jia, Yingming Chu, Xuezhi Zhang, Hui Ye. Helicobacter pylori Infection in Geriatric Patients: Current Situation and Treatment Regimens. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.713908
|
| 14 |
Raluca Ioana Dascălu, Alexandra Bolocan, Dan Nicolae Păduaru, Alexandru Constantinescu, Magda Mihaela Mitache, Anca Daniela Stoica, Octavian Andronic. Multidrug resistance in Helicobacter pylori infection. Frontiers in Microbiology 2023; 14 doi: 10.3389/fmicb.2023.1128497
|
| 15 |
Mengling Ouyang, Shupeng Zou, Qian Cheng, Xuan Shi, Minghui Sun. Comparative Efficacy and Safety of Potassium‐Competitive Acid Blockers and Proton Pump Inhibitors for First‐Line Helicobacter pylori Eradication Therapy: A Systematic Review and Network Meta‐Analysis. Helicobacter 2024; 29(6) doi: 10.1111/hel.13150
|
| 16 |
Qiuyue Huang, Zongming Shi, Hong Cheng, Hui Ye, Xuezhi Zhang. Efficacy and Safety of Modified Dual Therapy as the First-line Regimen for the Treatment of Helicobacter pylori Infection. Journal of Clinical Gastroenterology 2021; 55(10): 856 doi: 10.1097/MCG.0000000000001448
|
| 17 |
Zishao Zhong, Bingjie Zhan, Baohui Xu, Hengjun Gao. Achieving Helicobacter pylori eradication in the primary treatment requires a deep integration of personalization and standardization. Helicobacter 2022; 27(5) doi: 10.1111/hel.12916
|
| 18 |
Xiaoye Shi, Chunmei Wang, Fanjun Meng, Shaoze Ma, Guangqin Xu, Tingwei Liu, Xiaozhong Guo, Hongyu Li, Xingshun Qi. Impact of insufficient doses of medications on Helicobacter pylori eradication: a retrospective observational study. Postgraduate Medicine 2022; 134(7): 668 doi: 10.1080/00325481.2022.2105094
|
| 19 |
Ying Zhou, Ziqing Ye, Yuhuan Wang, Zhiheng Huang, Cuifang Zheng, Jieru Shi, Wenjuan Tang, Ping Zhang, Shengnan Wang, Ying Huang. Long‐term changes in the gut microbiota after triple therapy, sequential therapy, bismuth quadruple therapy and concomitant therapy for Helicobacter pylori eradication in Chinese children. Helicobacter 2021; 26(4) doi: 10.1111/hel.12809
|
| 20 |
Ran Han, Hong Lu, Ming-Wan Jiang, Ke-Wen Tan, Zhong Peng, Jia-Li Hu, Dian-Chun Fang, Chun-Hui Lan, Xiao-Ling Wu. Multicenter Study of Antibiotic Resistance Profile ofH. pyloriand Distribution of CYP2C19 Gene Polymorphism in Rural Population of Chongqing, China. Gastroenterology Research and Practice 2016; 2016: 1 doi: 10.1155/2016/8547686
|
| 21 |
Chao Peng, Yi Hu, Zhong‐Ming Ge, Quan‐Ming Zou, Nong‐Hua Lyu. Diagnosis and treatment ofHelicobacter pyloriinfections in children and elderly populations. Chronic Diseases and Translational Medicine 2019; 5(4): 243 doi: 10.1016/j.cdtm.2019.12.003
|
| 22 |
Shasha Chen, Weina Shen, Yuhuan Liu, Qiang Dong, Yongquan Shi. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial. Chinese Medical Journal 2023; 136(14): 1690 doi: 10.1097/CM9.0000000000002696
|
| 23 |
Endalew Gebeyehu, Desalegn Nigatu, Ephrem Engidawork, Yan Li. Helicobacter pylori eradication rate of standard triple therapy and factors affecting eradication rate at Bahir Dar city administration, Northwest Ethiopia: A prospective follow up study. PLOS ONE 2019; 14(6): e0217645 doi: 10.1371/journal.pone.0217645
|
| 24 |
Yingling Jiang, Lifang Huang, Lihua Zhou. Association between obesity and helicobacter pylori infection. Nutrition Clinique et Métabolisme 2022; 36(3): 210 doi: 10.1016/j.nupar.2022.07.003
|
| 25 |
Wen Zhong Liu, Yong Xie, Hong Lu, Hong Cheng, Zhi Rong Zeng, Li Ya Zhou, Ye Chen, Jiang Bin Wang, Yi Qi Du, Nong Hua Lu. Fifth Chinese National Consensus Report on the management ofHelicobacter pyloriinfection. Helicobacter 2018; 23(2) doi: 10.1111/hel.12475
|
| 26 |
Wen Ji, Wei-Qing Chen, Xu Tian. Efficacy of compoundLactobacillus acidophilustablets combined with quadruple therapy forHelicobacter pylorieradication and its correlation with pH value in the stomach: a study protocol of a randomised, assessor-blinded, single-centre study. BMJ Open 2018; 8(10): e023131 doi: 10.1136/bmjopen-2018-023131
|
| 27 |
Yao Chen, Qingyi Liu, Fulian Hu, Jizheng Ma. Identifying the best regimen for primary eradication of Helicobacter pylori: analysis of 240 cases. MicrobiologyOpen 2020; 9(11) doi: 10.1002/mbo3.1120
|
| 28 |
Miao Duan, Qingzhou Kong, Hui Wang, Yueyue Li. Optimal Duration of Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta‐Analysis. Helicobacter 2024; 29(5) doi: 10.1111/hel.13144
|
| 29 |
Yan Zhou, Zishao Zhong, Shengjuan Hu, Jing Wang, Yanhong Deng, Ximei Li, Xianmei Chen, Xue Li, Yuanyuan Tang, Xiaofei Li, Qian Hao, Jun Liu, Tian Sang, Yang Bo, Feihu Bai.
A Survey of
Helicobacter pylori
Antibiotic-Resistant Genotypes and Strain Lineages by Whole-Genome Sequencing in China
. Antimicrobial Agents and Chemotherapy 2022; 66(6) doi: 10.1128/aac.02188-21
|
| 30 |
Mika Miura, Masahiko Ohtaka, Mitsuhiko Hanawa, Naoki Shimura, Yoshioki Yoda, Sho Suzuki. Gastric Mucosal Atrophy Might Be Associated with the Efficacy of First-Line Therapy Using Vonoprazan for <i>Helicobacter pylori</i>. Open Journal of Gastroenterology 2017; 7(09): 243 doi: 10.4236/ojgas.2017.79026
|
| 31 |
Yong Xie, Xiaolin Pan, Yan Li, Huahong Wang, Yiqi Du, Jianming Xu, Jiangbin Wang, Zhirong Zeng, Ye Chen, Guoxin Zhang, Kaichun Wu, Dongsheng Liu, Nonghua Lv. New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese prospective, randomized, multicentre trial. Journal of Antimicrobial Chemotherapy 2018; 73(6): 1681 doi: 10.1093/jac/dky056
|
| 32 |
Ismael de Jesús Yepes Barreto, Claudia Osorio Marín, María Nicol Múnera Contreras. Eficacia y factores determinantes de la respuesta al tratamiento con claritromicina, esomeprazol y amoxacilina para la infección por H. Pylori.. Revista Ciencias Biomédicas 2016; 7(2): 258 doi: 10.32997/rcb-2016-2854
|
| 33 |
Ying An, Ya Wang, Shuang Wu, You-Hua Wang, Xing Qian, Zhen Li, Ying-Jun Fu, Yong Xie. Fourth-generation quinolones in the treatment of <i>Helicobacter pylori</i> infection: A meta-analysis. World Journal of Gastroenterology 2018; 24(29): 3302-3312 doi: 10.3748/wjg.v24.i29.3302
|
| 34 |
Olivia L. Wells, Sidharth Mishra, Hariom Yadav. Metabolism of Nutrients by Gut Microbiota. 2022; : 86 doi: 10.1039/9781839160950-00086
|
| 35 |
Xixi Guo, Xiaosa Zhao, Xi Lu, Liping Zhao, Qingxuan Zeng, Fenbei Chen, Zhimeng Zhang, Mengyi Xu, Shijiao Feng, Tianyun Fan, Wei Wei, Xin Zhang, Jing Pang, Xuefu You, Danqing Song, Yanxiang Wang, Jiandong Jiang. A deep learning-driven discovery of berberine derivatives as novel antibacterial against multidrug-resistant Helicobacter pylori. Signal Transduction and Targeted Therapy 2024; 9(1) doi: 10.1038/s41392-024-01895-0
|